# IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

IN RE TRICOR INDIRECT PURCHASER ANTITRUST LITIGATION	) ) C.A. No. 05-360 (KAJ)
THIS DOCUMENT RELATES TO:	(consolidated)
C.A. No. 05- 390	) ) )

# AMENDED NOTICE OF VIDEOTAPE DEPOSITION OF PENNSYLVANIA EMPLOYEES BENEFIT TRUST FUND PURSUANT TO FED. R. CIV. P. 30(b)(6) AND REQUEST FOR DOCUMENTS

To: All Counsel on the Attached Service List

PLEASE TAKE NOTICE that pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, counsel for Defendants shall take the deposition by oral examination of Pennsylvania Employees Benefit Trust Fund, on June 14, 2006 at 10:30 A.M., at the offices of Pennsylvania Employees Benefit Trust Fund, 150 South 43rd Street, Suite 1, Harrisburg, Pennsylvania or such other location agreed to by counsel. The deposition will be recorded by videotape as well as stenographically before a Notary Public or other officer authorized to administer oaths, and shall continue from day to day until completed, with such adjournments as to time and place as may be necessary.

NOTICE IS HEREBY GIVEN that pursuant to Fed. R. Civ. P. 30(b)(6), Pennsylvania Employees Benefit Trust Fund is required to designate one or more appropriate persons to testify on its behalf with respect to each of the matters set forth in Exhibit A attached hereto, and the person(s) so designated shall be required to testify as to each of those matters known or reasonably available to the corporation. Counsel for Pennsylvania Employees Benefit

Trust Fund has indicated that it designates William K. Schatzenbach, CFO and Interim Executive Director, for the deposition. You are invited to attend and cross-examine. Pennsylvania Employees Benefit Trust Fund must also produce documents respect to each of the matters set forth in Exhibit B attached hereto by May 18, 2006.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ James W. Parrett, Jr.

Mary B. Graham (#2256)
James W. Parrett, Jr. (#4292)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
Attorneys for Defendant Abbott Laboratories

#### OF COUNSEL:

William F. Cavanaugh, Jr.
Eugene M. Gelernter
Chad J. Peterman
Alexis Gander
PATTERSON, BELKNAP, WEBB & TYLER LLP
1133 Avenue of the Americas
New York, NY 10036-6710
(212) 336-2000

June 2, 2006 523080

### **DEFINITIONS AND INSTRUCTIONS**

- 1. The term "concerning" means relating to, referring to, describing, evidencing or constituting.
- 2. The terms "Your" or "Yours" means Pennsylvania Employees Benefit Trust Fund; all parents, subsidiaries, and affiliates thereof, all divisions, predecessors, successors and assigns of each of the foregoing; and all officers, directors, employees, agents, consultants, attorneys and all other persons acting or purporting to act on behalf of, or under the control of, each of the foregoing.
- 3. The term "Members" means persons or entities enrolled or otherwise covered (e.g., participants and beneficiaries) under Your prescription benefit or other health, welfare or medical plan.
- 4. The term "TriCor®" means any pharmaceutical product marketed under the trade name "TriCor®," at any time.
- 5. The term "Lofibra®" means any pharmaceutical product marketed under the trade name "Lofibra®," at any time.
- 6. The term "Antara®" means any pharmaceutical product marketed under the trade name "Antara®," at any time.
- 7. The term "Triglide®" means any pharmaceutical product marketed under the trade name "Triglide®," at any time.
- 8. The term "Third Party Payment" means a payment of money or other valuable consideration, including reimbursements, by You or on Your behalf for prescription drug products prescribed or dispensed to Members.

- 9. The term "Maintained Drug Formulary" or "Maintained Drug Formularies" means the comprehensive list(s) of brand-name and generic drugs covered under Your prescription benefit or other health, welfare or medical plans.
- 10. The term "document" is defined to be synonymous in meaning and equal in scope to the usage of this term in Federal Rule of Civil Procedure 34(a). A draft or non-identical copy is a separate document within the meaning of this term.
  - 11. The relevant time frame for these topics is January 1998 to the present.

# **EXHIBIT A**

You are requested to designate one or more officers, directors or managing agents, or other persons who consent to testify on Your behalf who have knowledge of the matters set forth herein.

#### **TOPICS**

- 1. Identification and authentication of Your contracts with pharmacy benefit managers, insurance companies, pharmacies or other entities, for the provision of pharmacy benefit management services or prescription drug coverage to Your Members.
- 2. Your policies, practices or procedures pertaining to the maintenance (including modifications thereto) of all Maintained Drug Formularies.
  - 3. Your control over Maintained Drug Formularies.
- 4. The status of (1) TriCor®, (2) Lofibra®, (3) Antara® and (4) Triglide® on all Maintained Drug Formularies.
- 5. Your discussions, considerations of, or decisions whether to add, delete or change the status of the following drugs on any Maintained Drug Formulary: (1) TriCor®, (2) Lofibra®, (3) Antara®, and (4) Triglide®.
- 6. Your communications with the manufacturers or suppliers of TriCor®, Lofibra®, Antara®, and Triglide® concerning: (a) the pricing (including rebates or other incentives) for TriCor®, Lofibra®, Antara®, and Triglide® or (b) the placement of TriCor®, Lofibra®, Antara®, and Triglide® on any Maintained Drug Formulary.
- 7. Your communications (including, internal communications or with the manufacturers or suppliers of Lofibra®, Antara®, and Triglide®) concerning any comparisons of, or similarities or differences between TriCor®, and Lofibra®, Antara®, or Triglide®.

- 8. Your communications to Members regarding TriCor®, Lofibra®, Antara®, and Triglide®.
- 9. Your efficacy, safety or consumer preference comparisons between any version of TriCor® and any version of Lofibra®, Antara® or Triglide®.
- 10. Your Third Party Payments for (1) TriCor®, (2) Lofibra®, (3) Antara®, and (4) Triglide®.

# **EXHIBIT B**

Defendants hereby incorporate by reference the Definitions and Instructions from Defendants' First Set of Requests for the Production of Documents and Things from the Third-Party Payer Plaintiffs.

1. Defendants hereby request the production of all documents relating or referring to the topics set forth in Exhibit A that have not already been produced in this litigation.

## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that on June 2, 2006 the foregoing was caused to be electronically filed with the Clerk of the Court using CM/ECF which will send electronic notification of such filing to all registered participants.

In addition, the undersigned hereby certifies that true and correct copies of the foregoing were caused to be served via electronic mail on June 2, 2006 upon the following parties:

REPRESENTING DIRECT PARTY PLAINTIFFS (C.A. 05-340):

Jeffrey S. Goddess

jgoddess@rmgglaw.com

Bruce E. Gerstein

bgerstein@garwingerstein.com

Barry S. Taus

btaus@garwingerstein.com

Adam M. Steinfeld

asteinfeld@garwingerstein.com

Daniel Berger

danberger@bm.net

Eric L. Cramer ecramer@bm.net

Peter Kohn

pkohn@bm.net

Linda P. Nussbaum lnussbaum@cmht.com

Steig D. Olson solson@cmht.com

REPRESENTING WALGREEN, ECKERD, KROGER, MAXI, CVS, RITE AID (C.A. 05-340):

Elizabeth M. McGeever emmcgeever@prickett.com

Scott E. Perwin

sperwin@kennynachwalter.com

Joseph T. Lukens

jlukens@hangley.com

REPRESENTING PACIFICARE (C.A. 05-340):

Jonathan L. Parshall jonp@msllaw.com

William Christopher Carmody bcarmody@susmangodfrey.com

John Turner

jturner@susmangodfrey.com

Shawn Rabin

srabin@susmangodfrey.com

Justin Nelson

jnelson@susmangodfrey.com

Cindy Tijerina

ctijerina@susmangodfrey.com

Ken Zylstra

kzylstra@sbclasslaw.com

Lyle Stamps

lstamps@sbclasslaw.com

**Steve Connolly** 

sconnolly@sbclasslaw.com

Mark Sandman

mms@rawlingsandassociates.com

Jeffrey Swann

js5@rawlingsandassociates.com

REPRESENTING INDIRECT PARTY PLAINTIFFS (C.A. 05-360):

Pamela S. Tikellis

Thomas M. Sobol

Patrick E. Cafferty

Jeffrey L. Kodroff

Bernard J. Persky

Mike Gottsch

A. Zachary Naylor

Robert Davis

**Brian Clobes** 

Michael Tarringer

Tim Fraser

David Nalven

Greg Matthews

Christopher McDonald

Kellie Safar

Theodore M. Lieverman

Pat Howard

tricor@chimicles.com

REPRESENTING TEVA PHARMACEUTICALS

(C.A. 02-1512):

Josy W. Ingersoll Karen E. Keller Bruce M. Gagala Christopher T. Holding

Ken Cohen Elaine Blais

tricor@ycst.com

REPRESENTING IMPAX LABORATORIES

(C.A. 03-120):

Mary Matterer

mmatterer@morrisjames.com

John C. Vetter

jvetter@kenyon.com

Asim Bhansali

abhansali@kvn.com

REPRESENTING FOURNIER

(ALL CASES):

Frederick L. Cottrell, III

Anne Shea Gaza Steven C. Sunshine Matthew P. Hendrickson Bradley J. Demuth Maggie DiMoscato Timothy C. Bickham

tricor@rlf.com

/s/ James W. Parrett, Jr.

James W. Parrett, Jr. (#4292)

523080